Community Healthcare Trust signed definitive agreements for five healthcare properties totaling $122.5M with expected returns between 9.1% and 9.75%, CFO David H. Dupuy disclosed in Q4 2025 earnings. The REIT issued zero shares under its ATM program during the quarter, planning to fund acquisitions through asset sales and existing revolver capacity.
The company's weighted average lease term expanded from 6.7 to 7 years in Q4. CHCT historically acquired $120M-$150M annually—split evenly between programmatic client deals ($50M-$60M) and brokered transactions—but suspended equity raises until stock pricing supports accretive issuance.
This disciplined capital allocation contrasts sharply with residential builders. Meritage Homes and competitors now offer mortgage rate buydowns and closing cost credits to offset affordability pressures, compressing builder margins while CHCT maintains occupancy at 100% without financing subsidies.
The bifurcation reflects sector-specific fundamentals. Healthcare real estate benefits from demographic tailwinds and tenant stability, while residential faces demand destruction from elevated mortgage rates. CHCT's pipeline targets post-construction occupancy, reducing development risk compared to speculative homebuilding.
Regulatory factors amplify the divergence. Income tax threshold freezes and property tax increases through 2028 hit residential owners directly, while triple-net lease structures in healthcare REITs pass operating costs to tenants. CHCT's long-term leases provide revenue visibility absent in transaction-dependent homebuilding.
The company is finalizing due diligence on a geriatric behavioral hospital sale but provided no closing timeline. Dupuy noted transaction progress without certainty, indicating selective capital recycling rather than distressed disposition.
For traders, the setup offers rotation opportunities. Homebuilder equities face margin compression and volume declines, while defensive healthcare REITs trade at yields 200-300 basis points above the 10-year Treasury despite operational stability. CHCT's 9%+ acquisition yields exceed most residential development returns after incentive costs.
The spread between CHCT's programmatic deal flow and homebuilders' incentive-laden sales suggests institutional capital is repricing real estate risk by subsector. Healthcare's recession-resistant cash flows command premiums over cyclical residential exposure as fiscal headwinds persist through 2028.